Efficient Chemotherapy of Rat Glioblastoma Using Doxorubicin-Loaded PLGA Nanoparticles with Different Stabilizers
Open Access
- 6 May 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (5), e19121
- https://doi.org/10.1371/journal.pone.0019121
Abstract
Chemotherapy of glioblastoma is largely ineffective as the blood-brain barrier (BBB) prevents entry of most anticancer agents into the brain. For an efficient treatment of glioblastomas it is necessary to deliver anti-cancer drugs across the intact BBB. Poly(lactic-co-glycolic acid) (PLGA) nanoparticles coated with poloxamer 188 hold great promise as drug carriers for brain delivery after their intravenous injection. In the present study the anti-tumour efficacy of the surfactant-coated doxorubicin-loaded PLGA nanoparticles against rat glioblastoma 101/8 was investigated using histological and immunohistochemical methods. The particles were prepared by a high-pressure solvent evaporation technique using 1% polyvinylalcohol (PLGA/PVA) or human serum albumin (PLGA/HSA) as stabilizers. Additionally, lecithin-containing PLGA/HSA particles (Dox-Lecithin-PLGA/HSA) were prepared. For evaluation of the antitumour efficacy the glioblastoma-bearing rats were treated intravenously with the doxorubicin-loaded nanoparticles coated with poloxamer 188 using the following treatment regimen: 3×2.5 mg/kg on day 2, 5 and 8 after tumour implantation; doxorubicin and poloxamer 188 solutions were used as controls. On day 18, the rats were sacrificed and the antitumour effect was determined by measurement of tumour size, necrotic areas, proliferation index, and expression of GFAP and VEGF as well as Isolectin B4, a marker for the vessel density. The results reveal a considerable anti-tumour effect of the doxorubicin-loaded nanoparticles. The overall best results were observed for Dox-Lecithin-PLGA/HSA. These data demonstrate that the poloxamer 188-coated PLGA nanoparticles enable delivery of doxorubicin across the blood-brain barrier in the therapeutically effective concentrations.Keywords
This publication has 28 references indexed in Scilit:
- Inhibition of brain tumor growth by intravenous poly(β- l -malic acid) nanobioconjugate with pH-dependent drug releaseProceedings of the National Academy of Sciences, 2010
- Targeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB)Journal of Drug Targeting, 2010
- Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parametersEuropean Journal of Pharmaceutics and Biopharmaceutics, 2010
- Increased Numbers of Injections of Doxorubicin Bound to Nanoparticles Lead to Enhanced Efficacy Against Rat Glioblastoma 101/8Journal of Nanoneuroscience, 2009
- Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effectsClinical Neuropathology, 2009
- Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesisAngiogenesis, 2006
- Lipid composition determines interaction of liposome membranes with Pluronic L61Biochimica et Biophysica Acta (BBA) - Biomembranes, 2005
- Analysis of Prion Strains by PrPSc Profiling in Sporadic Creutzfeldt–Jakob DiseasePLoS Medicine, 2005
- Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticlesInternational Journal of Cancer, 2004
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990